Cite

    Baiano, R. et al. (n.d.). Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab – comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms. Journal of drug assessment. p. 3. [Online].